Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer

Inclusion Criteria: * At least 18 years of age * Diagnosed with localized, prostate cancer and who have been offered curative therapy (radical prostatectomy; cryotherapy; brachytherapy; External Beam RadioTherapy (EBRT), and refused * Localized prostate cancer stage T1C up to T2A based on biopsy performed at least 6 weeks prior to enrollment * Gleason score ≤ 3+3 with ≤50% of sampled cores positive, and each positive core having a tumour length of ≤5 mm * Prostate Specific Antigen (PSA) \< 10 ng/mL * No prior treatment for prostate cancer * Signed Informed Consent Form Exclusion Criteria: * Any condition or history of illness or surgery that, in the opinion of the investigator and/or the Sponsor, might confound the results of the study or pose additional risks to the patient. * All patients whose current pre-operative cardiac evaluation does not show their fitness for a procedure requiring general anesthesia; * Patients with a prior history of viral or alcoholic hepatitis, and other patients felt to be at risk for hepatotoxicity including concomitant use of potentially hepatotoxic medications or dietary supplements; * Patients with a history of inflammatory bowel disease or other factors which may increase the risk of fistula formation; * Patients who have received any hormonal manipulation (excluding 5-alpha reductase inhibitors) or androgen supplements within the previous 6 months; * Patients previously treated by radiation therapy (external therapy or brachytherapy) or chemotherapy or any therapy for prostate cancer; * Patients who have received or are receiving chemotherapy for prostate carcinoma or other significant cancer; * Patients who have undergone previous TURP (trans-urethral resection of the prostate); * Patients with a history of urethral stricture disease * Patients with a history of acute urinary retention * Patients who are currently (within 10 days before the treatment procedure) receiving any medications having potential photosensitizing effects (e.g. tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics and griseofulvin) * Patients who are currently receiving anticoagulant drugs (within 10 days before the treatment procedure) (e.g.: coumadin, warfarin) * Patient who stopped long term treatment of acetylsalicylic acid (aspirin) or other anti platelets agents within 10 days prior to the treatment procedure; * Patient suspected of Disseminated Intravascular Coagulation (DIC) as defined by the presence of three out of the five following criteria: platelets decrease, increase of PT, increase of aPTT, fibrinogen decrease, D-Dimer increase; from the normal laboratory ranges; * Patient with a history of vasculitis or collagen vascular disease; * History of non compliance with medical therapy and medical recommendations or an unwillingness or inability to complete patient self-administered questionnaires; * Participation in a clinical study or receipt of an investigational treatment within the past 3 months; * A history of porphyria; * A history of sun hypersensitivity or photosensitive dermatitis; * Renal disorders (blood creatinine \> 1.5 x ULN) or known post mictional residue \> 150cc * Hepatic disorders (transaminases \> ULN, bilirubin \> ULN, GGT \> ULN). In case of slight abnormalities, another exam could be performed. If the results are within normal ranges, then the patient can be included; * Hematological disorders (white cells \< 2500/mm3, neutrophils \< 1500/mm3, platelets, \< 140.000/mm3, Hb ≤ 10 g/dL); * Patients with contra-indication to MRI (such as pace maker, metal prosthesis, etc.).